BIOMEA FUSION INC
1 day chart
Kickstart your portfolio with a U.S. stock on us
Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.
Sign up and fund a new Wall St account and get a full U.S. share.
Biomea Fusion, Inc. is a preclinical-stage biopharmaceutical company. The Company is focused on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. The Company has built FUSION System discovery platform to advance a pipeline of covalent small molecule product candidates. The Company's lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective covalent inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The Company is developing BMF-219 for the treatment of liquid and solid tumors that are dependent on menin, including leukemias containing the mixed lineage leukemia (MLL) fusion protein. The Company is also advancing other preclinical covalent programs for the treatment of select cancers.
Buy US stocks in Australia starting with BMEA. Open an account and start investing today!
Ready to start your investing journey with Stake?Open an account
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in BMEA
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.
Invest in BMEA
Buy BMEA from US$3 brokerage
Invest in 6,000+ U.S. stocks and ETFs
Own a slice of BMEA from only US$10 with fractional shares